More Positive Test Results For Plymouth Firm's Cholesterol DrugEsperion Therapeutics Inc. Tuesday announced positive results from a Phase 2a study of its drug candidate ETC-1002 when added to statin therapy in patients with high levels of low density lipoprotein cholesterol, the so-called bad cholesterol, in their blood.
Breast Cancer Clinical Trial Targets Cancer Stem CellsA major reason that breast cancer returns after treatment and spreads to other parts of the body is that current chemotherapy and radiation treatments do not kill the cancer stem cells. That premise provides the basis for a clinical trial open at the University of Michigan Comprehensive Cancer Center and two other sites testing a drug that has been found in laboratory studies to attack cancer stem cells.
Clinical Trial Tests Targeting Prostate Cancer TreatmentA new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout the country.
Aastrom Enrolls First Patients In Phase 2b Clinical Trial of Ixmyelocel-TAastrom Biosciences Inc. (Nasdaq:ASTM), the developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that the first patients have been enrolled in the ixCELL-DCM clinical trial.
Rockwell Medical Announces Iron Delivery Drug SFP Meets GoalsWixom-based Rockwell Medical Monday announced successful results from a clinical study of Soluble Ferric Pyrophosphate, its investigational iron-delivery drug now in Phase 3 clinical studies for the treatment of iron deficiency in hemodialysis patients.
AlphaCore Reports Positive Phase 1 Results For New Heart DrugAlphaCore Pharma announced Tuesday that results from the company’s Phase 1 clinical trial have met the primary endpoint by demonstrating the safety and tolerability of the drug ACP-501 (recombinant human LCAT).
New Treatment Possible For Type 2 DiabetesA study published online in the Journal of Biological Chemistry showed a new drug to treat diabetes being developed by Metabolic Solutions Development Co. LLC, MSDC-0602, improved insulin resistance and inflammation in obese mice.
Stryker Announces Positive Clinical Results From TrevoThursday at the European Stroke Conference in Lisbon, Portugal, Stryker announced positive results of the clincal trial of Stryker's Trevo 2, a tool for removing blood clots from the blood vessels of stroke patients.
ALS Patients Approved For More Stem CellsThree patients with amyotrophic lateral sclerosis will be permitted to receive a second dose of stem cells delivered directly to the spinal cord, in a clinical trial being led by the University of Michigan's Eva Feldman, M.D.
UM Part Of New Study Of Stem Cell Injections in Lou Gehrig's DiseaseThe first published results from an early-stage clinical trial show that spinal cord stem cells can be delivered safely into the spines of patients with the condition commonly known as Lou Gehrig's disease, opening the door for further research on this innovative approach.
DMC First in Michigan to Participate in Clinical Trial for Treating Heart FailureIn an effort toward the research and development of new and potentially breakthrough treatment options for patients with congestive heart failure, DMC Cardiovascular Institute has become the first hospital in Michigan and the seventh hospital across the United States to participate in the INOVATE-HF (INcrease Of VAgal TonE Heart Failure) clinical trial.
Henry Ford Pioneering New Treatment For Aggressive Brain TumorsHenry Ford Hospital's Hermelin Brain Tumor Center is the first U.S. hospital to start a new clinical trial for Toca 511 & Toca FC, a combination therapy under investigation for high-grade glioma, a fast-growing brain cancer that often recurs even after surgery, radiation treatment and chemotherapy.
Adeona Starts Phase II Trials Of New MS DrugAdeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had started a Phase II clinical trial of Trimesta (oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis in women.
CytoPherx Raises $34M To Move Into U.S. Clinical TrialsCytoPherx Inc. announced it has completed a $34 million round of funding. The funds will be used to complete United States clinical trials and gain FDA approval to commercialize the CytoPherx anti-inflammatory therapy for acute kidney injury.
Adeona Completes Enrollment In Phase II Trial Of MS DrugAdeona Pharmaceuticals Inc. said Monday that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta oral estriol drug candidate for relapsing-remitting multiple sclerosis in women.